Stock Scorecard
Stock Summary for Amneal Pharmaceuticals Inc - Class A (AMRX) - $5.87 as of 4/26/2024 8:53:23 PM EST
Total Score
7 out of 29
Currently on the following lists
None
Tim's Recommendation
Avoid
Growth List Algorithm Criteria for AMRX
Positive earnings growth | |
P/E ratio less than Industry P/E Ratio | |
P/E ratio less than Sector P/E Ratio | |
P/E ratio that is half the growth rate (or less) | |
Positive net cash position the past year and most recent quarter | |
Equity to debt ratio greater than 0.75 for past year and most recent quarter | |
Positive net income past year and 12 trailing months | |
Free cash flow ratio greater than 0 and less than 10 |
Small Cap List Algorithm Criteria for AMRX
Revenue growing by at least 20% average per year over the last 5 years | |
Market Capitalization under 2 billion | |
Price to Sales (P/S) ratio 12 trailing months less than Industry P/S ratio twelve trailing months | |
Price to Sales (P/S) ratio 12 trailing months less than Sector P/S ratio twelve trailing months | |
Net Income past year > Net Income prior year OR Net Income 12 trailing months > Net Income prior year OR Net Income 12 trailing months > Net Income past year |
Dividend List Algorithm Criteria for AMRX
Declared an ex-dividend date | |
Forward annual dividend rate greater than 2 | |
Positive net cash position the past year and most recent quarter | |
Equity to debt ratio greater than 0.75 for past year and most recent quarter | |
Current ratio most recent quarter greater than 2 |
Bonus Criteria for AMRX
P/E ratio less than five-year Average P/E ratio | |
Last Price to 52 Week Low Ratio Less Than 1 | |
Total Cash Per Share > Last Day Price | |
P/S Ratio < 1 | |
P/B Ratio < 1 |
Latest News for for AMRX
Financial Details for AMRX
Company Overview |
|
---|---|
Ticker | AMRX |
Company Name | Amneal Pharmaceuticals Inc - Class A |
Country | USA |
Description | Amneal Pharmaceuticals, Inc. develops, licenses, manufactures, markets and distributes generic and specialty pharmaceutical products for various dosage forms and therapeutic areas. The company is headquartered in Bridgewater, New Jersey. |
Sector Name | LIFE SCIENCES |
Industry Name | PHARMACEUTICAL PREPARATIONS |
Most Recent Quarter | 12/31/2023 |
Next Earnings Date | 5/3/2024 |
Stock Price History |
|
Last Day Price | 5.87 |
Last Day Price Updated | 4/26/2024 8:53:23 PM EST |
Last Day Volume | 959,053 |
Average Daily Volume | 1,737,208 |
52-Week High | 6.46 |
52-Week Low | 1.74 |
Last Price to 52 Week Low | 237.36% |
Valuation Measures |
|
Trailing PE | N/A |
Industry PE | 79.17 |
Sector PE | 56.64 |
5-Year Average PE | 5.07 |
Free Cash Flow Ratio | 19.57 |
Industry Free Cash Flow Ratio | 12.71 |
Sector Free Cash Flow Ratio | 30.65 |
Current Ratio Most Recent Quarter | 1.63 |
Total Cash Per Share | 0.30 |
Book Value Per Share Most Recent Quarter | 0.06 |
Price to Book Ratio | 86.10 |
Industry Price to Book Ratio | 5.66 |
Sector Price to Book Ratio | 22.15 |
Price to Sales Ratio Twelve Trailing Months | 0.71 |
Industry Price to Sales Ratio Twelve Trailing Months | 5.48 |
Sector Price to Sales Ratio Twelve Trailing Months | 5.17 |
Share Statistics |
|
Total Shares Outstanding | 308,554,000 |
Market Capitalization | 1,811,211,980 |
Institutional Ownership | N/A |
Dividends |
|
Ex-Dividend Date | N/A |
Last Dividend Amount | 0.00 |
Current Dividend Amount | 0.00 |
Dividend Aristocrat? | False |
Trailing Annual Dividend Rate | 0.00 |
Trailing Annual Dividend Yield | 0.00% |
Forward Annual Dividend Rate | 0.00 |
Forward Annual Dividend Yield | 0.00% |
5-Year Dividend Payments Count | 0 |
3-Year Average Dividend Yield | 0.00% |
5-Year Average Dividend Yield | 0.00% |
1-Year Dividend Growth Rate Percentage | 0.00% |
3-Year Dividend Growth Rate Percentage | 0.00% |
5-Year Dividend Growth Rate Percentage | 0.00% |
All-Time Dividend Growth Rate Percentage | 0.00% |
Dividend Payout Ratio | N/A |
Income Statement |
|
Quarterly Earnings Growth YOY | -94.90% |
Annual Earnings Growth | 70.71% |
Reported EPS 12 Trailing Months | -0.48 |
Reported EPS Past Year | 0.00 |
Reported EPS Prior Year | 0.64 |
Net Income Twelve Trailing Months | -79,265,000 |
Net Income Past Year | -79,265,000 |
Net Income Prior Year | -270,584,000 |
Quarterly Revenue Growth YOY | 1.20% |
5-Year Revenue Growth | 7.76% |
Balance Sheet |
|
Total Cash Most Recent Quarter | 91,542,000 |
Total Cash Past Year | 91,542,000 |
Total Cash Prior Year | 25,976,000 |
Net Cash Position Most Recent Quarter | -2,328,587,000 |
Net Cash Position Past Year | -2,328,587,000 |
Long Term Debt Past Year | 2,420,129,000 |
Long Term Debt Prior Year | 2,621,942,000 |
Total Debt Most Recent Quarter | 2,420,129,000 |
Equity to Debt Ratio Past Year | 0.01 |
Equity to Debt Ratio Most Recent Quarter | 0.01 |
Total Stockholder Equity Past Year | 19,781,000 |
Total Stockholder Equity Prior Year | 298,421,000 |
Total Stockholder Equity Most Recent Quarter | 19,781,000 |
Options |
|
Put/Call Ratio | 0.45 |
Has Options | Options Chain |
Liquidity Rating | |
Technical Analysis |
|
Yahoo Finance Chart | Yahoo Finance Chart |
MACD | -0.04 |
MACD Signal | -0.05 |
20-Day Bollinger Lower Band | 5.12 |
20-Day Bollinger Middle Band | 5.68 |
20-Day Bollinger Upper Band | 6.24 |
Beta | 1.35 |
RSI | 57.40 |
50-Day SMA | 4.39 |
200-Day SMA | 4.10 |
System |
|
Modified | 4/26/2024 5:47:06 PM EST |